## **CENTER FOR DRUG EVALUATION AND RESEARCH**

**APPLICATION NUMBER: NDA 19777/S6** 

## **CHEMISTRY REVIEW(S)**

CHEMIST'S REVIEW (If necessary, continue any item on 8" x 194" paper.  Key continuation to Item by number.)  3. NAME AND ADDRESS OF APPLICANT (City and State)		1. ORGANIZATION	2. NDA NUMBER
		HFD-110	19-777 4. AF NUMBER
ICI Pharmaceuticals Group			7-612
Wilmington, DE 19897		<del>-</del>	5. SUPPLEMENT (
	•	,	NUMBER(S) DAT
NAME OF DRUG	7. NONPR	OPRIETARY NAME	
Zestril Tablets	Lisino	- oril	S006 8/2
			3,5
SUPPLEMENT(S) PROVIDES FOR:			
rework procedure for 40 mg tablets.			9. AMENDMENTS AND (Reports, etc.) DATE
			Y001 7/ <del>25/</del> 8
10. PHARMACOLOGICAL CATEGORY	1	11. HOW DISPENSED	12. RELATED IND/NDA
Antihypertensive	-	□ RX □ °	TC NDA 19-558
3. DOSAGE FORM (S)	14.POTEN	* * *	
TCM	5, 10	), 20 and 40 mg	
15. CHEMICAL NAME AND STRUCTURE			16. RECORDS AND REI
	•		CURRENT
			REVIEWED
17. COMMENTS		_	
	-		
<del></del>		•	-
		•	
•		_	
<u> </u>		<u>-</u>	
		• • • • • • • • • • • • • • • • • • •	-
		·	
	•		
		•	_